Wells Fargo analyst Derek Archila lowered the firm’s price target on Argenx (ARGX) to $1,247 from $1,317 and keeps an Overweight rating on the shares. While management’s Q1 and Opex commentary may be weighing on shares, the firm also thinks it suggests well north of 30% revenue growth for Vyvgart in 2026. Wells remains confident Argenx becomes a $100B market cap in the next 12-24 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $940 from $915 at H.C. Wainwright
- Argenx price target raised to $944 from $925 at Citizens
- Argenx price target lowered to $1,227 from $1,248 at Stifel
- Vyvgart’s Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
- Argenx Posts First Operating Profit on Surging VYVGART Sales and Expanding Autoimmune Pipeline